Another strike against Merck's sugammadex as FDA nixes advisory panel confab

Merck & Co. ($MRK) says it's expecting yet another rejection from the FDA for its anesthesia drug sugammadex, as the agency scrapped an advisory panel's review of the drug slated for next week. The FDA told the company it plans additional site inspections before it hands the info over to an advisory committee. Report